By
WilD on
January 21, 2012
Substance abuse with diabetes, doctors who don’t like the way you’re using your insulin pump — these are just a few of the prickly issues we deal with here at our weekly advice column, Ask D’Mine, hosted by veteran type 1, diabetes author and community educator Wil Dubois.
Send us your queries related to life with diabetes — nothing is off-limits here! (except of course specific medical instructions for your own care; that’s what doctors are for)
{Need…
Read more »
As we know, diabetes doesn’t just affect the person with diabetes — it affects the whole family. So we’re back with another edition of our Partner Follies series, a place where the partners of PWDs can share what it’s like for them to live with and love someone with diabetes.
Today, we’re thrilled to introduce you to Jackie Farrell, the wonderful and sweet wife of Bernard Farrell, long-time DOC blogger and one of our DiabetesMine Design…
Read more »
By
AmyT on
January 18, 2012
Paula Deen is facing the music, on the eve of her birthday nonetheless (tomorrow). She and her publicist must have had a phone-a-thon today as she made herself available to the media, inevitably to answer to accusations of hypocrisy, profiteering, and just being a downright bad role model for people with diabetes everywhere. I got a scant 15 minutes on the phone with her, and all I can say is, she sure sounded like a…
Read more »
By
AmyT on
January 17, 2012
In case you haven’t heard, famous butter-and-cream Southern supreme chef Paula Deen has announced that she is a type 2 diabetic… and that she has partnered with Novo Nordisk in a campaign promoting their drug, Victoza. The way the Internet is all abuzz with this news, you’d think President Obama had been diagnosed with diabetes. But apparently the fact that Paula Deen, renowned for her carb-laden cookbooks and television shows, now has type 2 diabetes…
Read more »
By
AmyT on
January 17, 2012
In the area of beta cell preservation, there’s a (sort of) new name in the spotlight: Andromeda Biotech, Ltd. with its DiaPep277 treatment. Based in Israel, this company announced last month that phase III clinical trials showed significant preservation of C-peptide levels, a marker for assessing insulin secretion by pancreatic cells. Andromeda joins the ranks of companies like Tolerx and Macrogenics/Lilly, who’ve been vocal about their work to preserve beta cell functioning in newly diagnosed patients…
Read more »
